4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) and Scholar Rock (NASDAQ:SRRK – Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership.
Volatility & Risk
4D Molecular Therapeutics has a beta of 2.74, meaning that its stock price is 174% more volatile than the S&P 500. Comparatively, Scholar Rock has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings and price targets for 4D Molecular Therapeutics and Scholar Rock, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| 4D Molecular Therapeutics | 1 | 1 | 9 | 0 | 2.73 |
| Scholar Rock | 0 | 0 | 6 | 1 | 3.14 |
Institutional and Insider Ownership
99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 7.3% of 4D Molecular Therapeutics shares are held by company insiders. Comparatively, 19.2% of Scholar Rock shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares 4D Molecular Therapeutics and Scholar Rock’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| 4D Molecular Therapeutics | N/A | -28.00% | -26.16% |
| Scholar Rock | N/A | -145.60% | -91.83% |
Earnings and Valuation
This table compares 4D Molecular Therapeutics and Scholar Rock”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| 4D Molecular Therapeutics | $17,000.00 | 15,092.08 | -$100.84 million | ($2.85) | -1.95 |
| Scholar Rock | $33.19 million | 125.40 | -$165.79 million | ($2.35) | -18.92 |
4D Molecular Therapeutics has higher earnings, but lower revenue than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
4D Molecular Therapeutics beats Scholar Rock on 9 of the 14 factors compared between the two stocks.
About 4D Molecular Therapeutics
4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.
About Scholar Rock
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for 4D Molecular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
